Medivation Inc (MDVN) 80.93 $MDVN Uptrend Call
Post# of 273258
Posted On: 09/02/2016 7:00:53 AM
Medivation Inc (MDVN) 80.93 $MDVN
Uptrend Call Working As Medivation Stock Rises 28.3% (MDVN)
Comtex SmarTrend(R) - Wed Aug 31, 1:06AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 28.34% as of today's recent price of $80.36.
MDVN: 80.93 (+0.37)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.93 (+0.37), JNJ: 119.08 (-0.26), GE: 31.20 (-0.04), GS: 168.51 (-0.95), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21), MYL: 41.92 (-0.44), BWXT: 39.12 (+0.31), BA: 129.90 (+0.45), VZ: 52.56 (+0.23), MS: 31.91 (-0.15)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Thu Aug 25, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medivation, Inc. (NASDAQ: MDVN) ("Medivation" or the "Company"
relating to the proposed buyout of Medivation by Pfizer Inc.
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders
BusinessWire - Thu Aug 25, 1:50PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
Mark Vickery - Zacks Investment Research - Wed Aug 24, 9:11AM CDT
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
MDVN: 80.93 (+0.37), LZB: 26.55 (-0.12), TSLA: 200.77 (-11.24), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21)
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Wed Aug 24, 4:02AM CDT
Medivation (NASDAQ:MDVN) was downgraded from Buy to Hold at Brean Capital today. The stock closed yesterday at $80.27 on volume of 16.8 million shares, above average daily volume of 4.9 million. Medivation (NASDAQ:MDVN) is currently priced 25.1% above its average consensus analyst price target of $60.15. The stock should find initial support at its 50-day moving average (MA) of $44.77 and further support at its 200-day MA of $43.26.
MDVN: 80.93 (+0.37)
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. -MDVN
PR Newswire - Tue Aug 23, 7:43PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation" or "the Company" (Nasdaq- MDVN-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer".
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders
BusinessWire - Tue Aug 23, 2:29PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
Medivation Has Returned 28.3% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Tue Aug 23, 1:26PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 28.32% as of today's recent price of $80.35.
MDVN: 80.93 (+0.37)
Stock Market News for August 23, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:10AM CDT
Benchmarks closed mostly in the red on Monday after a decline in crude prices weighed on energy sector and eventually on the Dow and S&P 500
CST: 47.98 (+0.17), TSLA: 200.77 (-11.24), VRX: 29.12 (+0.09), PFE: 34.68 (-0.12), HAL: 43.21 (+0.20), SLB: 78.96 (-0.04), DLPH: 70.30 (-0.36), MS: 31.91 (-0.15), MDVN: 80.93 (+0.37), PXD: 180.22 (+1.17), MRO: 15.11 (+0.09), CVX: 100.21 (-0.37), MBLY: 49.19 (+0.30)
The Purge is Over: These Speculative Stocks are Ready to Soar!
Greg Guenthner - Daily Reckoning - Tue Aug 23, 8:50AM CDT
This post The Purge is Over: These Speculative Stocks are Ready to Soar! appeared first on Daily Reckoning . There’s plenty of action happening beyond the grasp of the major averages. Today, Greg Guenthner shows you another red-hot trade to your...
MDVN: 80.93 (+0.37)
InvestorsObserver releases covered-call reports for Medivation, Potash Corporation of Saskatchewan, Dominos Pizza, MOMO Inc. and JC Penney
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DPZ, JCP, MDVN, MOMO, and POT.
MDVN: 80.93 (+0.37), POT: 17.81 (-0.29), JCP: 9.44 (+0.01), DPZ: 149.01 (-0.56), MOMO: 24.00 (-0.01)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 3:50AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12), SNY: 38.41 (-0.06)
Uptrend Call Working As Medivation Stock Rises 28.3% (MDVN)
Comtex SmarTrend(R) - Wed Aug 31, 1:06AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 28.34% as of today's recent price of $80.36.
MDVN: 80.93 (+0.37)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.93 (+0.37), JNJ: 119.08 (-0.26), GE: 31.20 (-0.04), GS: 168.51 (-0.95), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21), MYL: 41.92 (-0.44), BWXT: 39.12 (+0.31), BA: 129.90 (+0.45), VZ: 52.56 (+0.23), MS: 31.91 (-0.15)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Thu Aug 25, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medivation, Inc. (NASDAQ: MDVN) ("Medivation" or the "Company"
relating to the proposed buyout of Medivation by Pfizer Inc. MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders
BusinessWire - Thu Aug 25, 1:50PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
Mark Vickery - Zacks Investment Research - Wed Aug 24, 9:11AM CDT
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
MDVN: 80.93 (+0.37), LZB: 26.55 (-0.12), TSLA: 200.77 (-11.24), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21)
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Wed Aug 24, 4:02AM CDT
Medivation (NASDAQ:MDVN) was downgraded from Buy to Hold at Brean Capital today. The stock closed yesterday at $80.27 on volume of 16.8 million shares, above average daily volume of 4.9 million. Medivation (NASDAQ:MDVN) is currently priced 25.1% above its average consensus analyst price target of $60.15. The stock should find initial support at its 50-day moving average (MA) of $44.77 and further support at its 200-day MA of $43.26.
MDVN: 80.93 (+0.37)
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. -MDVN
PR Newswire - Tue Aug 23, 7:43PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation" or "the Company"
(Nasdaq- MDVN-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer". MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders
BusinessWire - Tue Aug 23, 2:29PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12)
Medivation Has Returned 28.3% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Tue Aug 23, 1:26PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 28.32% as of today's recent price of $80.35.
MDVN: 80.93 (+0.37)
Stock Market News for August 23, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:10AM CDT
Benchmarks closed mostly in the red on Monday after a decline in crude prices weighed on energy sector and eventually on the Dow and S&P 500
CST: 47.98 (+0.17), TSLA: 200.77 (-11.24), VRX: 29.12 (+0.09), PFE: 34.68 (-0.12), HAL: 43.21 (+0.20), SLB: 78.96 (-0.04), DLPH: 70.30 (-0.36), MS: 31.91 (-0.15), MDVN: 80.93 (+0.37), PXD: 180.22 (+1.17), MRO: 15.11 (+0.09), CVX: 100.21 (-0.37), MBLY: 49.19 (+0.30)
The Purge is Over: These Speculative Stocks are Ready to Soar!
Greg Guenthner - Daily Reckoning - Tue Aug 23, 8:50AM CDT
This post The Purge is Over: These Speculative Stocks are Ready to Soar! appeared first on Daily Reckoning . There’s plenty of action happening beyond the grasp of the major averages. Today, Greg Guenthner shows you another red-hot trade to your...
MDVN: 80.93 (+0.37)
InvestorsObserver releases covered-call reports for Medivation, Potash Corporation of Saskatchewan, Dominos Pizza, MOMO Inc. and JC Penney
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DPZ, JCP, MDVN, MOMO, and POT.
MDVN: 80.93 (+0.37), POT: 17.81 (-0.29), JCP: 9.44 (+0.01), DPZ: 149.01 (-0.56), MOMO: 24.00 (-0.01)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 3:50AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.93 (+0.37), PFE: 34.68 (-0.12), SNY: 38.41 (-0.06)
(0)
(0)Scroll down for more posts ▼